1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BINEX Co., Ltd.

BINEX Co., Ltd.

053030.KQ
BINEX Co., Ltd.KR flagKOSDAQ
7,180.00
KRW
+280.00
- -
228.67BMarket Cap
BINEX Co., Ltd.
053030.KQ
(KOSDAQ)

Recent

price

7,180.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,912.54
3,168.49
2,546.49
2,486.48
2,341.45
2,422.57
2,639.25
2,466.22
3,332.78
4,021.06
4,272.02
4,321.8
5,061.19
5,005.31
4,175.46
5,274.8
5,149.61
Revenue per Share
-233.5
201.97
-360
-101.71
405
-232
-98
-357
203
273
206
614
402
151
-1,126
-101
-403.67
Basic EPS, GAAP
-870.02
-861.21
-798.27
-191.37
-134.41
-2,369.57
-50.23
168.99
349.91
56.52
333.22
284.15
-626.4
-400.12
-667.12
-1,456.9
-1,130.88
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1,060.17
1,199.21
693.12
559.34
907.13
635.94
368.02
-40.24
272.24
555.25
800.36
1,462
1,870.68
2,023.16
1,189.5
1,227.78
1,013.32
Book Value per Share
2,615.38
3,089.82
2,737.46
2,910.98
3,430.75
4,468.88
4,221.08
3,884.65
4,732.64
5,149.66
5,509.15
5,499.1
5,621.15
5,091.74
5,151.87
5,281.32
5,084.48
Tangible Book Value per Share
16
17
22
24
26
29
31
32
31
31
31
31
31
31
31
32
32
Basic Weighted Avg Shares
47,243
53,124
54,823
59,513
59,892
71,138
80,924
78,026
104,043
125,259
132,976
134,399
156,677
154,825
130,051
168,475
164,003
Sales/Revenue/Turnover
-3.85
7.3
-0.2
-6.9
3.94
8.53
-2.46
-9.67
6.61
9
12.14
9.75
10.96
0.67
-23.65
-2.69
-8.57
Operating Margin (%)
2,876
2,711
3,880
5,948
6,207
6,339
8,090
8,983
8,985
9,060
5,677
6,004
8,301
9,892
12,432
13,894
14,035
Depreciation Expense
-3,788
3,386
-7,750
-2,434
10,360
-6,813
-3,005
-11,295
6,337
8,504
6,412
19,094
12,445
4,671
-35,071
-3,226
-12,856
Net Income, GAAP
- -
9.27
- -
- -
9.22
- -
- -
- -
- -
21.1
- -
21.47
18.83
6.36
- -
- -
- -
Effective Tax Rate (%)
-8.02
6.37
-14.14
-4.09
17.3
-9.58
-3.71
-14.48
6.09
6.79
4.82
14.21
7.94
3.02
-26.97
-1.91
-7.84
Profit Margin (%)
33,737
18,133
15,640
20,974
44,039
49,666
23,190
21,973
21,961
36,037
91,736
75,597
10,688
6,251
352
50,218
38,061
Working Capital
16,505
6,035
9,900
5,324
2,950
20,954
8,350
3,000
- -
229
44,590
45,252
1,533
5,578
4,873
60,466
60,037
LT Debt
55,635
70,583
91,782
98,967
113,079
148,607
141,775
131,727
152,268
161,379
174,036
181,174
192,283
181,325
181,607
187,456
180,023
Total Equity
- -
4.35
- -
- -
1.8
- -
- -
- -
- -
4.94
- -
4.46
5.78
0.4
- -
- -
- -
Return on Invested Capital (%)
- -
11.76
- -
- -
34.09
- -
- -
- -
- -
26.62
- -
22.86
13.43
5.72
- -
- -
- -
Return on Capital (%)
-20.13
18.16
-44.25
-17.2
56.62
-32.54
-20.06
- -
- -
65.94
30.38
54.26
24.08
7.75
-70.4
-8.46
-35.78
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
36,214
36,661
46,661
LT Borrowings
44,822
56,653
56,400
LT Finance Leases
3,941
3,813
3,636
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
520,391
477,078
356,694

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
107,337
112,879
113,615
Cash, Cash Equivalents & STI
9,046
19,614
23,259
Accounts Receivable, Net
24,134
22,190
14,513
Inventories
41,893
40,023
40,471
Total Current Liabilities
66,412
62,660
75,553
Payables & Accruals
- -
- -
- -
ST Debt
36,214
36,661
46,661
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.56%
1.58%
3.22%
Free Cash Flow
-21.39%
-35.72%
123.95%
Net Income, GAAP
-76.77%
-168.24%
-90.8%
Sales/Revenue/Turnover
10.01%
6%
29.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29,710
31,472
32,911
35,958
130,051
2025
39,787
44,528
45,363
38,797
168,475
2026
35,315
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-316
-172
-382
- -
-1,126
2025
0.39
44.1
-30.3
- -
-101
2026
-301.99
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Aptevo Therapeutics Inc. (APVO)
Inventiva S.A. (IVA.PA)
WuXi Biologics (Cayman) Inc. (WXXWY)
Cognition Therapeutics, Inc. (CGTX)
Fennec Pharmaceuticals Inc. (FENC)
Tiansheng Pharmaceutical Group Co., Ltd. (002872.SZ)
Business
BINEX Co., Ltd. (053030.KQ) operates as a biopharmaceutical contract development and manufacturing organization (CDMO) in South Korea, providing comprehensive services from cell line development and process optimization to GMP manufacturing of drug substances and drug products; its offerings encompass cell cultivation in mammalian systems up to 5,000L scale, microbial fermentation, analytical method development, and production of biologics including monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, recombinant proteins, and DNA vaccines, alongside chemical pharmaceuticals such as digestive agents (Bisroot, GI tract regulators, antispasmodics, antiulcer drugs), NSAIDs, cardiovascular and urology products, hepatic protectors, ointments, creams, ophthalmic solutions, CNS agents, antibiotics, antifungals, cough and cold remedies, vitamins, nutrients, antihistamines, antivertigo agents, laxatives, and OTC products. Founded in 1957 and headquartered in Busan at 368-3 Dadae-ro, Saha-gu, the company serves domestic and international clients in the healthcare sector, including major pharmaceutical firms, with facilities certified by regulatory authorities such as FDA, EMA, PMDA, and MFDS, and operates the Korea Biotechnology Commercialization Center (KBCC). Recent developments include a record-breaking 20.8 billion KRW biosimilar production contract signed in September 2025 with a global bio company, a KRW 50 billion funding round from investors including Kiwoom Securities and Aju IB Investment, and ongoing CMO partnerships such as with PharmAbcine for olinvacimab production on its new 5,000L line, reinforcing its position in biologics manufacturing amid expanding global demand.